Description

Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim to treat, prevent, or potentially cure diseases, and both approaches have the potential to alleviate the underlying cause of genetic diseases and acquired diseases. The global cell and gene therapy market is set to increase by US$ 14.75 billion from 2022 to 2028, representing a compound annual growth rate (CAGR) of 29.1% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for cell and gene therapy. The global cell and gene therapy market is segmented on the basis of therapy type, product, application, and region. On the basis of therapy type, the global cell and gene therapy market has been segmented into gene therapy, cell therapy, and others. By product, the global cell and gene therapy market has been segmented into Zolgensma, Yescarta, Kymriah, Zynteglo, Maci, Tecartus, and others. Based on application, the global cell and gene therapy market is categorized into rare diseases, oncology, hematology, ophthalmology, neurology, and others. In terms of geography, the global cell and gene therapy market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America.

The global cell and gene therapy market is highly competitive. As of 2021, the major players in the global cell and gene therapy market were Amgen Inc., bluebird bio Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Novartis International AG, Orchard Therapeutics plc, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics Inc., Vericel Corporation.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cell and gene therapy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Therapy type: gene therapy, cell therapy, and others
Product: Zolgensma, Yescarta, Kymriah, Zynteglo, Maci, Tecartus, and others
Application: rare diseases, oncology, hematology, ophthalmology, neurology, and others
Region: North America, Asia Pacific, Europe, Middle East and Africa, and Latin America
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global cell and gene therapy market
– Pinpoint growth sectors and trends for investment

Table of Contents

1. Market definition
2. Research methodology
3. Market data and outlook
3.1 Market size estimates
3.2 Forecast
4. Cell and gene therapy market by therapy type
4.1 Gene therapy
4.2 Cell therapy
4.3 Others
5. Cell and gene therapy market by product
5.1 Zolgensma
5.2 Yescarta
5.3 Kymriah
5.4 Zynteglo
5.5 Maci
5.6 Tecartus
5.7 Others
6. Cell and gene therapy market by application
6.1 Rare diseases
6.2 Oncology
6.3 Hematology
6.4 Ophthalmology
6.5 Neurology
6.6 Others
7. Cell and gene therapy market by region
7.1 North America
7.2 Asia Pacific
7.3 Europe
7.4 Middle East and Africa
7.5 Latin America
8. Company profiles
8.1 Amgen Inc.
8.2 bluebird bio, Inc.
8.3 Dendreon Pharmaceuticals LLC
8.4 Gilead Sciences, Inc.
8.5 Novartis International AG
8.6 Orchard Therapeutics plc
8.7 Shenzhen SiBiono GeneTech Co., Ltd.
8.8 Spark Therapeutics, Inc.
8.9 Vericel Corporation
9. Appendix
9.1 About StrategyHelix
9.2 Disclaimer